Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma

DOI: 10.1186/s40880-017-0230-7

Keywords: Metastatic renal cell carcinoma, Sorafenib, Sunitinib, Quality of life

Full-Text   Cite this paper   Add to My Lib

Abstract:

Baseline clinicopathologic and prognostic characteristics of 184 patients with metastatic renal cell carcinoma (mRCC

Full-Text